Focus Partners Advisor Solutions LLC bought a new stake in shares of DaVita Inc. (NYSE:DVA – Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,259 shares of the company’s stock, valued at approximately $725,000.
A number of other institutional investors also recently made changes to their positions in the stock. Fifth Third Bancorp increased its position in DaVita by 831.4% during the 1st quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after purchasing an additional 34,287 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in DaVita by 30.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after purchasing an additional 10,477 shares in the last quarter. SG Americas Securities LLC lifted its holdings in DaVita by 27.4% in the 1st quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after purchasing an additional 45,609 shares in the last quarter. LSV Asset Management boosted its stake in shares of DaVita by 1.1% during the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of DaVita by 63.5% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock worth $9,770,000 after buying an additional 33,394 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.
DaVita Stock Down 2.0%
NYSE:DVA opened at $176.47 on Tuesday. The company has a market cap of $11.26 billion, a P/E ratio of 14.44, a P/E/G ratio of 0.60 and a beta of 0.88. The firm’s 50 day moving average is $217.03 and its two-hundred day moving average is $180.11. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.
Insider Transactions at DaVita
In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.90% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on DVA. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Barclays lifted their target price on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. UBS Group boosted their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Oppenheimer set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, DaVita presently has an average rating of “Hold” and an average target price of $221.75.
Check Out Our Latest Analysis on DaVita
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Read More
- Five stocks we like better than DaVita
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
